{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:05Z","timestamp":1791920825996,"version":"4.3.4"},"reference-count":78,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T00:00:00Z","timestamp":1685232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>The multidrug-resistant (MDR) human immunodeficiency virus 1 (HIV-1) infection is an unmet medical need. HIV-1 capsid plays an important role at different stages of the HIV-1 replication cycle and is an attractive drug target for developing therapies against MDR HIV-1 infection. Lenacapavir (LEN) is the first-in-class HIV-1 capsid inhibitor approved by the USFDA, EMA, and Health Canada for treating MDR HIV-1 infection. This article highlights the development, pharmaceutical aspects, clinical studies, patent literature, and future directions on LEN-based therapies. The literature for this review was collected from PubMed, authentic websites (USFDA, EMA, Health Canada, Gilead, and NIH), and the free patent database (Espacenet, USPTO, and Patent scope). LEN has been developed by Gilead and is marketed as Sunlenca (tablet and subcutaneous injection). The long-acting and patient-compliant LEN demonstrated a low level of drug-related mutations, is active against MDR HIV-1 infection, and does not reveal cross-resistance to other anti-HIV drugs. LEN is also an excellent drug for patients having difficult or limited access to healthcare facilities. The literature has established additive\/synergistic effects of combining LEN with rilpivirine, cabotegravir, islatravir, bictegravir, and tenofovir. HIV-1 infection may be accompanied by opportunistic infections such as tuberculosis (TB). The associated diseases make HIV treatment complex and warrant drug interaction studies (drug\u2013drug, drug\u2013food, and drug\u2013disease interaction). Many inventions on different aspects of LEN have been claimed in patent literature. However, there is a great scope for developing more inventions related to the drug combination of LEN with anti-HIV\/anti-TB drugs in a single dosage form, new formulations, and methods of treating HIV and TB co-infection. Additional research may provide more LEN-based treatments with favorable pharmacokinetic parameters for MDR HIV-1 infections and associated opportunistic infections such as TB.<\/jats:p>","DOI":"10.3390\/medicina59061041","type":"journal-article","created":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T15:29:52Z","timestamp":1685287792000},"page":"1041","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection"],"prefix":"10.3390","volume":"59","author":[{"given":"Tafadzwa","family":"Dzinamarira","sequence":"first","affiliation":[{"name":"School of Health Systems and Public Health, University of Pretoria, Pretoria 0002, South Africa"},{"name":"ICAP, Columbia University, Harare P.O. Box 28, Zimbabwe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-8667","authenticated-orcid":false,"given":"Mazen","family":"Almehmadi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4117-5811","authenticated-orcid":false,"given":"Ahad Amer","family":"Alsaiari","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-7748","authenticated-orcid":false,"given":"Mamdouh","family":"Allahyani","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulelah","family":"Aljuaid","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1377-9247","authenticated-orcid":false,"given":"Abdulaziz","family":"Alsharif","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6186-461X","authenticated-orcid":false,"given":"Abida","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-0828","authenticated-orcid":false,"given":"Mehnaz","family":"Kamal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-9847","authenticated-orcid":false,"given":"Ali A.","family":"Rabaan","sequence":"additional","affiliation":[{"name":"Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia"},{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"},{"name":"Department of Public Health and Nutrition, The University of Haripur, Haripur 22610, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal H.","family":"Alfaraj","sequence":"additional","affiliation":[{"name":"Pediatric Department, Abqaiq General Hospital, First Eastern Health Cluster, Abqaiq 33261, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-9462","authenticated-orcid":false,"given":"Bashayer M.","family":"AlShehail","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Department, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7029-3089","authenticated-orcid":false,"given":"Nouf","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shams M.","family":"AlShehail","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah 21487, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-1040","authenticated-orcid":false,"given":"Mohd","family":"Imran","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ceccarelli, G., Giovanetti, M., Sagnelli, C., Ciccozzi, A., d\u2019Ettorre, G., Angeletti, S., Borsetti, A., and Ciccozzi, M. (2021). Human Immunodeficiency Virus Type 2: The Neglected Threat. Pathogens, 10.","DOI":"10.3390\/pathogens10111377"},{"key":"ref_2","unstructured":"World Health Organization (2023, February 23). HIV-AIDS. Available online: https:\/\/www.who.int\/health-topics\/hiv-aids#tab=tab_1."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chatzidaki, I., Curteis, T., Luedke, H., Mezzio, D.J., Rhee, M.S., McArthur, E., and Eddowes, L.A. (2022). Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus. Value Health.","DOI":"10.1016\/j.jval.2022.12.011"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Nikolopoulos, G.K., and Tsantes, A.G. (2022). Recent HIV Infection: Diagnosis and Public Health Implications. Diagnostics, 12.","DOI":"10.3390\/diagnostics12112657"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202206210","article-title":"Prevention and Initial Management of HIV Infection","volume":"175","author":"Feinberg","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e25449","DOI":"10.1002\/jia2.25449","article-title":"The challenge of HIV treatment in an era of polypharmacy","volume":"23","author":"Back","year":"2020","journal-title":"J. Int. AIDS Soc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.37201\/req\/s03.08.2022","article-title":"Global strategy in the treatment of HIV infection in 2022","volume":"35","author":"Rosas","year":"2022","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/COH.0000000000000761","article-title":"Update on treatment as prevention of HIV illness, death, and transmission: Sub-Saharan Africa HIV financing and progress towards the 95-95-95 target","volume":"17","author":"Gupta","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"fuac040","DOI":"10.1093\/femsre\/fuac040","article-title":"New antiretroviral inhibitors and HIV-1 drug resistance: More focus on 90% HIV-1 isolates?","volume":"47","author":"Ndashimye","year":"2023","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.drudis.2019.03.013","article-title":"New targets for HIV drug discovery","volume":"24","author":"Puhl","year":"2019","journal-title":"Drug. Discov. Today"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QCO.0000000000000896","article-title":"Lenacapavir and the novel HIV-1 capsid inhibitors: An emerging therapy in the management of multidrug-resistant HIV-1 virus","volume":"36","author":"Lee","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40265-022-01786-0","article-title":"Lenacapavir: First Approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: A first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Shaik","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_14","unstructured":"Gilead (2023, February 23). Lenacapavir. Available online: https:\/\/www.gilead.com\/utility\/search?q=lenacapavir."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S2352-3018(22)00375-7","article-title":"Lenacapavir in first-line therapy","volume":"10","author":"Orkin","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: A randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s15006-022-1912-x","article-title":"Lenacapavir\u2014Der erste Kapsid-Inhibitor","volume":"164","author":"Walter","year":"2022","journal-title":"MMW Fortschr. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1056\/NEJMe2204376","article-title":"Lenacapavir for HIV-1\u2014Potential Promise of a Long-Acting Antiretroviral Drug","volume":"386","author":"Marrazzo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"CAPELLA Study Investigators. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection","volume":"386","author":"DeJesus","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_20","unstructured":"European Medicines Agency (2023, February 23). Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sunlenca-epar-product-information_en.pdf."},{"key":"ref_21","unstructured":"Center For Drug Evaluation And Research (2023, February 23). Product Quality Review(s), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/215973,215974Orig1s000ChemR.pdf."},{"key":"ref_22","unstructured":"United States Food and Drug Administration (2023, February 23). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm."},{"key":"ref_23","unstructured":"European Medicines Agency (2023, February 23). Sunlenca. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sunlenca#authorisation-details-section."},{"key":"ref_24","unstructured":"Health Canada (2023, February 23). Product Monograph Including Patient Medication Information. Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00068216.PDF."},{"key":"ref_25","unstructured":"Center For Drug Evaluation And Research (2023, February 23). Labeling, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/215973,215974Orig1s000lbl.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rossi, E., Meuser, M.E., Cunanan, C.J., and Cocklin, S. (2021). Structure, Function, and Interactions of the HIV-1 Capsid Protein. Life, 11.","DOI":"10.3390\/life11020100"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103593","DOI":"10.1016\/j.isci.2021.103593","article-title":"GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factors","volume":"25","author":"Selyutina","year":"2021","journal-title":"iScience"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1126\/science.abb4808","article-title":"Structural and mechanistic bases for a potent HIV-1 capsid inhibitor","volume":"370","author":"Bester","year":"2020","journal-title":"Science"},{"key":"ref_29","unstructured":"Bauer, L.E., Gorman, E.M., Mulato, A.S., Rhee, M.S., Rowe, C.W., Sellers, S.P., Stefanidis, D., Tse, W., Yant, S.R., and Chiu, A. (2020). Capsid Inhibitors for the Treatment of HIV. (Application Publication Number WO2020018459A1), PCT Patent."},{"key":"ref_30","unstructured":"Neogi, U., Sonnerborg, A., Singh, K., Quinn, T.P., and Gallazzi, F. (2022). Peptide Inhibitors for the Inhibition of HIV Capsid. (Application Publication Number US2022306690A1), U.S. Patent."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4155\/fmc-2022-0008","article-title":"HIV-1 capsid inhibitors: A sword to destroy the virus","volume":"14","author":"Zhang","year":"2022","journal-title":"Future Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"854974","DOI":"10.3389\/fmicb.2022.854974","article-title":"HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor Lenacapavir","volume":"13","author":"Reinosa","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zhuang, S., and Torbett, B.E. (2021). Interactions of HIV-1 Capsid with Host Factors and Their Implications for Developing Novel Therapeutics. Viruses, 13.","DOI":"10.3390\/v13030417"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41594-022-00913-5","article-title":"A molecular switch modulates assembly and host factor binding of the HIV-1 capsid","volume":"30","author":"Schirra","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"ref_36","unstructured":"Bauer, L.E., Chiu, A., Gorman, E.M., Mulato, A.S., Rhee, M.S., Rowe, C.W., Sellers, S.P., Stefanidis, D., Tse, W.C., and Yant, S.R. (2020). Capsid Inhibitors for the Treatment of HIV. (Application Publication Number US2020038389A1), United States Patent."},{"key":"ref_37","unstructured":"Graupe, M., Henry, S.J., Link, J.O., Rowe, C.W., Saito, R.D., Schroeder, S.D., Stefanidis, D., Tse, W.C., and Zhang, J.R. (2018). Therapeutic compounds. (Number US10071985B2), U.S. Patent."},{"key":"ref_38","unstructured":"European Medicines Agency (2023, February 23). Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/sunlenca-epar-public-assessment-report_en.pdf."},{"key":"ref_39","unstructured":"Center For Drug Evaluation And Research (2023, February 23). Integrated Review, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/215973,215974Orig1s000IntegratedR.pdf."},{"key":"ref_40","unstructured":"National Institutes of Health (2023, February 23). National Library of Medicine, Available online: https:\/\/www.clinicaltrials.gov\/."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3018(21)00161-2","article-title":"Highlights from the 11th IAS Conference on Science","volume":"8","author":"Harris","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Cespedes, M., Das, M., Hojilla, J.C., Blumenthal, J., Mounzer, K., Ramgopal, M., Hodge, T., Torres, T.S., Peterson, C., and Shibase, S. (2022). Proactive strategies to optimize engagement of Black, Hispanic\/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0267780"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/jac\/dkab503","article-title":"Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study","volume":"77","author":"Margot","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Cilento, M.E., Ong, Y.T., Tedbury, P.R., and Sarafianos, S.G. (2022). Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations. Viruses, 14.","DOI":"10.3390\/v14061202"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jiph.2022.09.011","article-title":"Selenium and COVID-19: A spotlight on the clinical trials, inventive compositions, and patent literature","volume":"15","author":"Alshammari","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/13543776.2022.2045948","article-title":"Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: A patent review from 1998 to 2021","volume":"32","author":"Imran","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Imran, M., Khan, S.A., Alshammari, M.K., Alqahtani, A.M., Alanazi, T.A., Kamal, M., Jawaid, T., Ghoneim, M.M., Alshehri, S., and Shakeel, F. (2022). Discovery, Development, Inventions and Patent Review of Fexinidazole: The First All-Oral Therapy for Human African Trypanosomiasis. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020128"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Imran, M., Arora, M.K., Chaudhary, A., Khan, S.A., Kamal, M., Alshammari, M.M., Alharbi, R.M., Althomali, N.A., Alzimam, I.M., and Alshammari, A.A. (2022). MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature. Biomedicines, 10.","DOI":"10.3390\/biomedicines10112793"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Almehmadi, M., Allahyani, M., Alsaiari, A.A., Alshammari, M.K., Alharbi, A.S., Hussain, K.H., Alsubaihi, L.I., Kamal, M., Alotaibi, S.S., and Alotaibi, A.N. (2022). A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak. Viruses, 14.","DOI":"10.3390\/v14091870"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Imran, M., Asdaq, S.M.B., Khan, S.A., Unnikrishnan, M.D., Alamri, A.S., Alsanie, W.F., Alhomrani, M., Mohzari, Y., Alrashed, A., and AlMotairi, M. (2021). Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080710"},{"key":"ref_51","unstructured":"Brizgys, G., Canales, E., Chou, C.H., Graupe, M., Halcomb, R.L., Hu, Y.E., Lazerwith, S.E., Link, J.O., Liu, Q., and Lu, Y. (2018). Therapeutic Compounds. (Number US9951043B2), U.S. Patent."},{"key":"ref_52","unstructured":"Shi, B. (2022). Solid Forms of an HIV Capsid Inhibitor. (Number US11267799B2), U.S. Patent."},{"key":"ref_53","unstructured":"Graupe, M., Henry, S.J., Link, J.O., Saito, R.D., Schroeder, S.D., Stefanidis, D., Tse, W.C., and Zhang, J.R. (2020). Therapeutic Compounds. (Number US10654827B2), U.S. Patent."},{"key":"ref_54","unstructured":"Brizgys, G., Canales, E., Chou, C.H., Graupe, M., Halcomb, R.L., Hu, Y.E., Lazerwith, S.E., Link, J.O., Liu, Q., and Lu, Y. (2021). Therapeutic Compounds. (Application Publication Number US2021009555A1), U.S. Patent."},{"key":"ref_55","unstructured":"Brizgys, G., Canales, E., Chou, C.H., Graupe, M., Halcomb, R.L., Hu, Y.E., Lazerwith, S.E., Link, J.O., Liu, Q., and Lu, Y. (2018). Therapeutic Compounds. (Application Publication Number US2018273508A1), U.S. Patent."},{"key":"ref_56","unstructured":"Brizgys, G., Canales, E., Chou, C.H., Graupe, M., Hu, Y.E., Link, J.O., Liu, Q., Lu, Y., Saito, R.D., and Schroeder, S.D. (2014). Therapeutic Compounds. (Application Publication Number US2014303164A1), U.S. Patent."},{"key":"ref_57","unstructured":"Shi, B. (2022). Solid Forms of an HIV Capsid Inhibitor. (Application Publication Number US2022251069A1), U.S. Patent."},{"key":"ref_58","unstructured":"Xu, L., and Hong, Z. (2022). Combination Therapy for HIV with Adenosine Derivative and Capsid Inhibitors. (Application Publication Number WO2022159877A1), PCT Patent."},{"key":"ref_59","unstructured":"Li, J., Liu, X., Makadzange, A.T., Martin, S.R., Schmidt, S., Shehata, H., Stemeseder, F., Svarovskaia, E., and Boopathy, A. (2022). HIV Vaccines and Methods of Using. (Application Publication Number WO2022155258A1), PCT Patent."},{"key":"ref_60","unstructured":"De, L.P.L., Nejati, E., Shih, H.W., Subramanian, R., and Tang, H. (2021). Pharmaceutical Compositions Comprising Bictegravir. (Application Publication Number WO2021236944A1), PCT Patent."},{"key":"ref_61","unstructured":"Akhavein, N., Chu, K., and Velthuisen, E. (2022). Pharmaceutical Compositions Comprising Cabotegravir. (Application Publication Number KR20220112771A), Korean Patent."},{"key":"ref_62","unstructured":"Autio, S., Branham, K.E., Filice, J.A., Gibson, J.W., Leonard, J.J., Matriano, J., Moro, W., Sekar, M., Snyder, C.A., and Strickley, R.G. (2021). Long-Acting Formulations of Tenofovir Alafenamide. (Application Publication Number WO2021011891A1), PCT Patent."},{"key":"ref_63","unstructured":"Neogi, U., Sonnerborg, A., Singh, K., Quinn, T.P., and Gallazzi, F. (2020). Peptide Inhibitors for the Inhibition of HIV Capsid. (Application Publication Number WO2020247933A2), PCT Patent."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/QCO.0000000000000803","article-title":"Immunotherapeutic approaches to HIV cure and remission","volume":"35","author":"Lee","year":"2022","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_65","unstructured":"(2023, February 23). Clinicalinfo Federally Approved Clinical Practice Guidelines for, HIV\/AIDS, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jac\/dkac388","article-title":"Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals","volume":"78","author":"Nka","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1038\/s41467-022-33662-6","article-title":"Prion-like low complexity regions enable avid virus-host interactions during HIV-1 infection","volume":"13","author":"Wei","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_68","unstructured":"Jiang, L., Lin, D.W., Mitchell, M.L., Roberts, E., and Schwarzwalder, G. (2021). Tetracyclic Compounds for Treating HIV Infection. (Application Publication Number WO2021173522A1), PCT Patent."},{"key":"ref_69","unstructured":"Jiang, L., Lin, D.W., Mitchell, M.L., Roberts, E., and Schwarzwalder, G.M. (2022). Tetracyclic Compounds for Treating HIV Infection. (Application Publication Number KR20220145368A), Korean Patent."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e0180422","DOI":"10.1128\/mbio.01804-22","article-title":"Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir","volume":"13","author":"Bester","year":"2022","journal-title":"mBio"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e02057","DOI":"10.1128\/AAC.02057-20","article-title":"Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes","volume":"65","author":"Margot","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/venereology2010001","article-title":"Prevalence of Comorbidities and Associated Factors among HIV Patients Attending Antiretroviral Clinics in the Tamale Metropolis, Ghana","volume":"2","author":"Hattoh","year":"2023","journal-title":"Venereology"},{"key":"ref_73","unstructured":"Baca, M., Blair, W.S., Carr, B.A., Clancy, S.B., Goldsmith, J., Hung, M.S., Kanwar, M., Moldt, B., Nagel, M., and Pace, C.S. (2022). Multi-specific Antigen Binding Molecules Targeting HIV and Methods of Use. (Application Publication Number WO2022046644A1), PCT Patent."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Roomaney, R.A., van Wyk, B., and Wyk, V.P.-V. (2022). Aging with HIV: Increased Risk of HIV Comorbidities in Older Adults. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19042359"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Dzinamarira, T., Imran, M., and Muvunyi, C.M. (2022). The Management of Infectious Diseases in Comorbidity with Tuberculosis. Medicina, 58.","DOI":"10.3390\/medicina58101406"},{"key":"ref_76","unstructured":"Chu, H., Gonzalez, B.A.Z., Guo, H., Han, X., Jiang, L., Li, J., Mitchell, M.L., Pyun, H.J., Schroeder, S.D., and Schwarzwalder, G.M. (2021). Bridged Tricyclic Carbamoylpyridone Compounds and Their Pharmaceutical Use. (Application Publication Number CN113874079A), Chinese Patent."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11684-011-0124-z","article-title":"Practices, challenges, and opportunities: HIV\/AIDS treatment with traditional Chinese medicine in China","volume":"5","author":"Wang","year":"2011","journal-title":"Front. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1753-4887.2007.tb00298.x","article-title":"Update: Effects of antioxidant and non-antioxidant vitamin supplementation on immune function","volume":"65","author":"Webb","year":"2007","journal-title":"Nutr. Rev."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1041\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:43:56Z","timestamp":1760125436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/6\/1041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,28]]},"references-count":78,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["medicina59061041"],"URL":"https:\/\/doi.org\/10.3390\/medicina59061041","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,28]]}}}